BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target
BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.
Share
Why It Matters
An analyst who studies stocks thinks United Therapeutics looks really good now. They believe the company could be worth a lot more money soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.